1. Sea-blue histiocytes in acute myeloid leukemia with trisomy 9

   • Katsuya Yamamoto
   • Yosuke Minami
   • Hironobu Minami

   Images in Hematology 16 August 2016 Pages: 531 - 533

   

2. ADAMTS13: more than a regulator of thrombosis

   • Yun Feng
   • Xueyin Li
   • Suhua Chen

   Review Article 01 October 2016 Pages: 534 - 539

   

3. Abnormal histone acetylation of CD8⁺ T cells in patients with severe aplastic anemia

   • Weiwei Qi
   • Li Yan
   • Zonghong Shao

   Original Article 02 August 2016 Pages: 540 - 547

   

4. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan

   • Haruhiko Ninomiya
   • Naoshi Obara
   • Yuzuru Kanakura

   Original Article 27 July 2016 Pages: 548 - 558

   

5. Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia

   • Yanfang Li
   • Hui He
   • Songping Luo

   Original Article 25 July 2016 Pages: 559 - 565

   

6. Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms

   • M. Monika Belickova
   • Michaela Dostalova Merkerova
   • Anna Jonasova

   Original Article 14 July 2016 Pages: 566 - 573

   

7. Clinical outcome and efficacy of current anti-leukemic therapy for leptomeningeal involvement in acute myeloid leukemia

   • Ji Hyun Kwon
   • Young-il Koh
   • Inho Kim

   Original Article 18 July 2016 Pages: 574 - 581

   

8. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value

   • Patricia Rubio
   • B. Campos
   • C. N. Alonso

   Original Article 19 July 2016 Pages: 582 - 590

   

9. Clinical features and treatment outcome of Epstein–Barr virus-positive nodal T-cell lymphoma

   • Ki Sun Jung
   • Su-Hee Cho
   • Won Seog Kim

   Original Article 25 July 2016 Pages: 591 - 595

   

10. Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma

    • Shinsuke Iida
    • Kensei Tobinai
    • Takaaki Chou

    Original Article 26 July 2016 Pages: 596 - 604

    

11. Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia

    • Akihisa Hino
    • Hitoshi Yoshida
    • Jun Ishikawa

    Original Article 26 July 2016 Pages: 605 - 611

    

12. Co-occurrence of hyperleukocytosis and elevated fibrin–fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia

    • Kunimoto Ichikawa
    • Yoko Edahiro
    • Michiaki Koike

    Original Article 25 July 2016 Pages: 612 - 620

    

13. Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor

    • Makiko Uemura
    • Osamu Imataki
    • Norimitsu Kadowaki

    Original Article 04 August 2016 Pages: 621 - 627

    

14. Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis

    • Li Fu
    • Jingshi Wang
    • Zhao Wang

    Original Article 18 July 2016 Pages: 628 - 635